Eicosatrienoic acid

Eicosatrienoic Acid: A Comprehensive Reference

1. Identity and Nomenclature

Eicosatrienoic acid (sometimes rendered icosatrienoic acid) is not a single compound but rather a family designation. The term denotes any straight-chain polyunsaturated fatty acid (PUFA) that contains 20 carbons and 3 double bonds. Three biologically significant isomers exist, distinguished by the position of the first double bond from the methyl (omega) terminus of the carbon chain and, therefore, by their omega-series classification.

• 5,8,11-Eicosatrienoic acid (20:3n-9) — "Mead acid": Mead acid (MA, 5,8,11-eicosatrienoic acid) is an n-9 polyunsaturated fatty acid (PUFA) and a marker of essential fatty acid deficiency. This structure shares identical double bonds at the 5, 8, and 11 positions with arachidonic acid.
• 8,11,14-Eicosatrienoic acid (20:3n-6) — Dihomo-γ-linolenic acid (DGLA): DGLA (20:3n-6) is an omega-6 fatty acid formed inside the body from gamma-linolenic acid (GLA; 18:3n-6).
• 11,14,17-Eicosatrienoic acid (20:3n-3) — omega-3 ETA: A minor omega-3 PUFA notable for its presence in skin tissue and photoprotective research.

It is important to distinguish Mead acid from another eicosatrienoic acid, dihomo-γ-linolenic acid (DGLA), which has double bonds at the 8, 11, and 14 positions and is an n-6 PUFA. DGLA has various unique activities and is metabolized to specific lipid mediators that differ from Mead acid-derived mediators. Because the literature applies the generic label "eicosatrienoic acid" to all three isomers, precise identification of which compound is under discussion requires attention to the lipid shorthand notation and the omega-series designation.

The molecular formula shared by all three isomers is C₂₀H₃₄O₂ (molecular weight approximately 308.5 g/mol). All are colorless to pale-yellow oily liquids at room temperature.

2. Natural Sources and Common Forms/Preparations

2.1 Mead Acid (20:3n-9)

In mammals, 5,8,11-eicosatrienoic acid (Mead acid, 20:3n-9) is synthesized from oleic acid during a state of essential fatty acid deficiency (EFAD). Mead acid is a minor fatty acid in essential fatty acid (EFA)-sufficient healthy subjects but is found at increased levels in EFA deficiency. Most dietary staples provide enough EFA to maintain the percentage of n-9 HUFA in tissues below 2% of HUFA.

Mead acid is synthesized de novo in the body and is present not only in conditions of EFA deficiency but also in major normal tissues. As an exogenous dietary source, an ETrA-rich oil extracted from a cultured fungus was used in research to prepare diets with varying levels of ETrA. Eicosatrienoic acid (20:3n-3; also known as Mead acid) can be produced using various mutants of Mortierella alpina, but yields are rather low and, without further development work, are unlikely to represent realistic commercial sources.

2.2 DGLA (20:3n-6)

Gamma-linolenic acid (GLA), which is found only in some terrestrial plant species, such as evening primrose (Oenothera biennis) or borage (Borago officinalis), is easily converted to eicosatrienoic acid [i.e., DGLA], which greatly favors the formation of series-1 eicosanoids. DGLA is found in filamentous fungi, such as Mortierella species, and in various common foods, such as meat, eggs, and seafood, but in small amounts. There are only trace amounts of DGLA found in organ meats; otherwise it must be synthesized from GLA.

For DGLA from M. alpina mutants, the content of this fatty acid reaches about 23–25% of the total fatty acids, representing a reasonable route to obtaining oils rich in this particular PUFA. Practically, DGLA can be obtained two ways: directly (as DGLA-enriched oil) or indirectly by taking GLA from evening primrose, borage, or black currant seed oils and allowing endogenous enzymes to convert it.

2.3 Omega-3 ETA (11,14,17-Eicosatrienoic Acid, 20:3n-3)

Palmitic acid (C16:0), stearic acid (C18:0), palmitoleic acid (C16:1), oleic acid (C18:1), linoleic acid (C18:2), and (all-cis)-11,14,17-eicosatrienoic acid (ETA, C20:3n-3) have been determined as major fatty acids in human epidermal tissue. It is a minor omega-3 PUFA in dietary contexts. The omega-3 ETA is an intermediate in the elongation/desaturation pathway leading from alpha-linolenic acid toward eicosapentaenoic acid (EPA). It is not commercially available as a standalone supplement in widely documented preparations.

2.4 Supplement Forms

For DGLA specifically, supplement forms that appear in the clinical literature include soft-gel capsules filled with DGLA-enriched oil derived from fungal fermentation of Mortierella species. DGLA-enriched oil (direct form), if available, is the most predictable way to raise serum DGLA within 2–4 weeks. Clinical studies have used standardized capsules to deliver defined DGLA amounts. Evening primrose oil, borage seed oil, and black currant seed oil are widely available as dietary supplements whose primary route of DGLA delivery is via endogenous conversion from their GLA content.

3. Historical and Traditional Use

No discrete traditional-medicine use of isolated eicosatrienoic acid isomers exists in historical pharmacopoeias, primarily because these fatty acids were not identified as individual chemical entities until the mid-twentieth century. The relevant traditional uses belong to the plant oils from which precursors are derived.

Eicosatrienoic acid has been recognized for its significance in addressing essential fatty acid deficiencies. During the early and mid-20th century, researchers discovered that in cases where omega-3 and omega-6 fatty acids were scarce, the human body could synthesize Mead acid as a compensatory mechanism. This process was particularly noted in populations with restricted access to diverse dietary fats.

Evening primrose oil, the principal GLA-rich dietary oil that serves as DGLA's precursor, has a long history of use in North American indigenous traditions. Members of the Ojibwe, Potawatomi, and other nations are documented to have applied poultices and decoctions of Oenothera seeds and leaves for skin conditions, bruising, and inflammatory complaints, though these preparations were not understood in terms of their fatty acid content at the time.

The scientific isolation of Mead acid as a distinct compound dates to 1956. Mead acid was first identified by Mead and Slaton in rats fed a fat-deficient diet and was determined to be derived from oleic acid. This discovery firmly placed Mead acid in the context of experimental nutritional biochemistry rather than traditional medicine.

4. Biosynthesis and Biochemical Identity

4.1 The Biosynthetic Pathway

All three eicosatrienoic acid isomers share a common biosynthetic context: the elongation/desaturation cascade of C18 fatty acid precursors. There is evidence that omega-3, omega-6, and omega-9 fatty acids compete for the same desaturase enzymes. These enzymes indicate preferences for the different series of fatty acids in the following order: omega-3 > omega-6 > omega-9. The synthesis of the omega-9 fatty acid eicosatrienoic acid (20:3n-9), also known as Mead acid, increases only when dietary intakes of omega-3 and omega-6 fatty acids are very low.

For DGLA, the conversion pathway is: linoleic acid (from food oils) → GLA (via delta-6 desaturase) → DGLA (via elongase) → arachidonic acid (via delta-5 desaturase).

For Mead acid specifically: in mammals, 5,8,11-eicosatrienoic acid (Mead acid, 20:3n-9) is synthesized from oleic acid during a state of essential fatty acid deficiency. Mead acid is thought to be produced by the same enzymes that synthesize arachidonic acid and eicosapentaenoic acid. Research has further identified the specific molecular enzymes involved: knockdown of Elovl5, Fads1, or Fads2 decreased the level of Mead acid in cultured cells.

For the omega-3 ETA (20:3n-3), it sits as an intermediate in the elongation of alpha-linolenic acid toward EPA. When dietary omega-3 and omega-6 intake is adequate, the omega-9 pathway (Mead acid synthesis) is suppressed because those preferred substrates outcompete oleic acid for the desaturase enzymes.

4.2 Endogenous Distribution

If the EFA intake from the diet is not sufficient, the liver produces long-chain polyunsaturated fatty acids from oleic acid, and the end product is 5,8,11-eicosatrienoic acid (Mead acid). Thus, the production of Mead acid is indirectly associated with the supply of EFAs in the diet, and an elevated Mead acid in serum is an indicator of essential fatty acid deficiency.

Importantly, Mead acid is not entirely absent even in EFA-sufficient individuals. Mead acid can be synthesized due to topical or temporal EFA deficiency, such as in avascular tissues, even in an EFA-sufficient status. In terms of human skin specifically, 11,14,17-eicosatrienoic acid (the omega-3 ETA) was significantly increased in photoaged human epidermis in vivo and also in acutely UV-irradiated human skin in vivo, while it was significantly decreased in intrinsically aged human epidermis.

5. Key Constituents and Mechanisms of Action

5.1 Mead Acid (20:3n-9): Mechanisms

Mead acid is distributed in various normal tissues and can be converted to several specific lipid mediators by lipoxygenase and cyclooxygenase. This conversion is due to Mead acid having a structure similar to that of arachidonic acid (ARA) and having identical double bonds at the 5, 8, and 11 positions. The properties of most lipid mediators derived from Mead acid remain unclear but may be related to the physiological and pharmacological activities of Mead acid.

A key documented mechanism is inhibition of pro-inflammatory leukotriene B4 (LTB4) synthesis. Mead acid (5,8,11-eicosatrienoic acid), an oleic acid metabolite, was shown to ameliorate skin inflammation in dinitrofluorobenzene-induced allergic contact hypersensitivity by inhibiting neutrophil infiltration and leukotriene B4 production by neutrophils. Additional mechanistic research has identified a PPAR-α pathway: Mead acid was found to ameliorate skin inflammation through a peroxisome proliferator-activated receptor (PPAR)-α-mediated pathway by inhibiting keratinocyte abnormalities such as keratinocyte hyperplasia and the gene expression of neutrophil chemoattractants.

Mead acid also interacts with eicosanoid biosynthesis: eicosatrienoic acid (20:3) is an alternative precursor for prostaglandin synthesis.

5.2 DGLA (20:3n-6): Mechanisms

One of the notable functions of DGLA concerns anti-inflammation and anti-proliferation diseases, especially cancers. This is based on the ability of DGLA to interfere in cellular lipid metabolism and eicosanoid (cyclooxygenase and lipoxygenase) biosynthesis. DGLA can be further converted by inflammatory cells to 15-(S)-hydroxy-8,11,13-eicosatrienoic acid and prostaglandin E1 (PGE1). These compounds possess both anti-inflammatory and anti-proliferative properties.

The increase in DGLA relative to ARA is able to attenuate the biosynthesis of ARA metabolites — i.e., 2-series prostaglandins, 4-series leukotrienes, and platelet-activating factor (PAF) — and exerts an anti-inflammatory effect in human subjects.

With regard to COX enzyme kinetics: increasing the endogenous formation of PGE1 requires optimization of cellular lipid enrichment with DGLA and effective cyclooxygenase-dependent oxygenation of substrate DGLA relative to ARA. DGLA and ARA had similar affinities (Km values) and maximal reaction rates (Vmax) for COX-2, whereas ARA was metabolized preferentially by COX-1.

DGLA has emerged as a significant molecule differentiating healthy and inflamed tissues. Its position at a pivotal point of metabolic pathways leading to anti-inflammatory derivatives — or via arachidonic acid to pro-inflammatory lipid mediators — makes this n-6 PUFA an intriguing research subject. The balance of ARA to DGLA is probably a critical factor affecting inflammatory processes in the body.

5.3 Omega-3 ETA (11,14,17-Eicosatrienoic Acid, 20:3n-3): Mechanisms

The increased ETA content in the epidermis of photoaged human skin and acute UV-irradiated human skin is associated with enhanced expression of human elongase 1 and calcium-independent phospholipase A2. ETA was shown to inhibit matrix metalloproteinase (MMP)-1 expression after UV-irradiation, and inhibition of ETA synthesis using elongase inhibitors increased MMP-1 expression. These results suggest that UV increases ETA levels, which may have a photoprotective effect in human skin.

6. Scientific Evidence by Area of Use

6.1 Essential Fatty Acid Deficiency Detection (Mead Acid / 20:3n-9)

The most robustly evidenced clinical role of any eicosatrienoic acid isomer is the use of Mead acid as a biomarker for essential fatty acid deficiency (EFAD). This is a firmly established, clinically applied diagnostic metric — not an exploratory association.

The Holman Index, defined by the ratio of Mead acid to arachidonic acid (triene:tetraene, T:T) in the plasma, has historically served as the method for diagnosis of EFAD, with the threshold diagnostic value at ≥0.20. The Holman Index is derived from the body's natural metabolic response to EFA deprivation — increasing synthesis of Mead acid — and thus remains broadly applicable across various populations.

Holman first described the use of the triene (Mead acid) to tetraene (arachidonic acid) ratio (T:T ratio) to identify EFAD, which he classified as 0.4. Decades later, the Holman index threshold of 0.2 is commonly used to diagnose EFAD based on further data from Holman et al. in healthy controls.

A triene:tetraene (T:T) ratio >0.2 is considered biochemical EFAD, although signs and symptoms of EFAD are detected at ratios >0.4. Elevation of the Holman index precedes the development of clinical signs of EFAD and may appear as early as 7–10 days following the restriction of EFAs, particularly when continuous fat-free feeding prevents mobilization of adipose tissue stores of linoleic acid.

Evidence strength: The use of Mead acid elevation as a biomarker of EFAD is supported by decades of clinical data and is applied in parenteral nutrition management. However, the use of the Holman Index (triene:tetraene ratio) alone may lead to an inaccurate diagnosis of EFAD in certain clinical contexts, particularly with newer multicomponent lipid injectable emulsions. The Holman index should be calculated only from plasma fatty acid profiles, as that is how its diagnostic utility was established. The cutoff of 0.2 indicating deficiency is not applicable to other samples (e.g., erythrocytes or isolated plasma phospholipids), which may have different baseline fatty-acid compositions.

6.2 Inflammation and Leukotriene Inhibition (Mead Acid and DGLA)

Animal and in-vitro evidence (Mead acid): An ETrA-rich oil extracted from a cultured fungus was used to prepare diets which had varying levels of ETrA (0–8 g/kg diet) in combination with linoleic acid. All diets were sufficient in essential fatty acids. Groups of rats were fed these diets for 4 weeks, after which leukocyte fatty acid content and leukotriene B4 (LTB4) synthesis were measured. ETrA was efficiently incorporated into peritoneal exudate cell (PEC) phospholipids, with no evident saturation observed at levels up to 10 mol/100 mol total fatty acids in peritoneal exudate cells. This constitutes animal-level evidence for anti-inflammatory effects of dietary Mead acid via LTB4 suppression.

Animal evidence (Mead acid, contact dermatitis): Mead acid was shown to suppress retinol-induced irritant contact dermatitis in a murine model, inhibiting keratinocyte abnormalities such as keratinocyte hyperproliferation.

In-vitro and ex-vivo (DGLA, atherosclerosis-related endpoints): Gamma-linolenic acid and prostaglandin E1, upstream precursor and key metabolite respectively of DGLA, acted in an anti-atherogenic manner. The actions of DGLA extended to other key atherosclerosis-associated cell types with attenuation of endothelial cell proliferation and migration of smooth muscle cells in response to platelet-derived growth factor. This study provides novel insights into the molecular mechanisms underlying the anti-atherogenic actions of DGLA but supports only further assessments on its protective effects in vivo and in human trials.

Evidence strength for inflammation: Predominantly animal and in vitro. The mechanisms are plausible and internally consistent, but controlled human clinical trials targeting Mead acid as an anti-inflammatory intervention are absent from the published literature as of the time of writing.

6.3 Allergic and Atopic Conditions (DGLA)

Human RCT: The effects of DGLA on pollen-induced allergic symptoms were investigated in healthy adults in a randomized, double-blind, placebo-controlled, parallel-group study comprising healthy Japanese men and women. Each subject received four 250-mg capsules providing 314 mg DGLA/day (DGLA group, n = 18) or olive oil (placebo group, n = 15) for 15 weeks. The results of this study suggest that DGLA is effective in reducing allergic symptoms caused by pollen. At the time of publication, no prior human intervention study had examined the effects of DGLA.

Human open-label study (DGLA via GLA/evening primrose oil, atopic dermatitis): One study investigated whether evening primrose oil (EPO) supplementation results in an increase in plasma GLA and its metabolite DGLA correlating with clinical improvement of atopic dermatitis (AD), assessed by the SCORAD index. The open study included 21 patients with AD. EPO (4–6 g) was administered daily for 12 weeks. A significant increase in plasma GLA and DGLA levels and a decrease in the objective SCORAD were observed 4 and 12 weeks after initiation of EPO treatment. This association, while positive, is from an open-label study without a control arm and cannot be regarded as definitive.

Counterpoint — systematic review evidence for GLA: A major systematic review pooling dozens of randomized trials found no meaningful benefit of oral evening primrose or borage oil on physician- or patient-rated eczema outcomes compared with placebo. Since GLA is the dietary precursor to DGLA and eczema is a condition where DGLA-mediated mechanisms are proposed, this negative finding from a large pooled analysis weighs against the efficacy of the indirect dietary approach.

Evidence strength: Preliminary to modest. One small randomized controlled trial in pollen allergy exists for direct DGLA supplementation; atopic dermatitis data rely on the upstream precursor GLA, where systematic reviews are not confirmatory.

6.4 Cardiovascular and Platelet Biology (DGLA)

DGLA is a precursor to prostaglandin PGE1, which inhibits platelet aggregation and inflammation, produces vasodilation, inhibits cholesterol biosynthesis and thrombus formation, regulates immune responses, and reduces blood pressure.

In lab and ex-vivo platelet models, DGLA can be turned into 15-HETrE, which dampens platelet aggregation and interferes with pro-thrombotic signaling cascades.

The inability to convert precursor fatty acids to DGLA is associated with various pathologic and physiologic conditions such as aging, diabetes, alcoholism, atopic dermatitis, rheumatoid arthritis, cancer, and cardiovascular disease.

Evidence strength: Biochemical and ex-vivo evidence is coherent and mechanistically sound. Randomized controlled human trials specifically examining DGLA supplementation for cardiovascular endpoints are not identified in the current literature. Clinical data remain scarce and further well-designed studies should be actively promoted.

6.5 Skin Health and Photoprotection (20:3n-3 omega-3 ETA)

Human observational/biopsy data: 11,14,17-eicosatrienoic acid (ETA), an omega-3 PUFA, was significantly increased in photoaged human epidermis and in acutely UV-irradiated human skin in vivo, while it was significantly decreased in intrinsically aged human epidermis. The increased ETA content in the epidermis of photoaged skin and acute UV-irradiated human skin is associated with enhanced expression of human elongase 1 and calcium-independent phospholipase A2.

Animal study (topical ETA, UV damage): Female HR-1 hairless mice were topically treated with vehicle only, 0.1% ETA, or 1% ETA once a day for 3 successive days after one-time UV irradiation (200 mJ/cm²) on dorsal skins. Skin biopsy was carried out on the fourth day (72 hours after UV irradiation). ETA was found to attenuate UV-induced epidermal and dermal thickness and infiltration of inflammatory cells.

ETA was shown to inhibit matrix metalloproteinase (MMP)-1 expression after UV-irradiation; inhibition of ETA synthesis using elongase inhibitors increased MMP-1 expression.

Evidence strength: Animal (in vivo) and human biopsy data suggest a biologically plausible photoprotective role. No controlled human intervention trials of topical or oral 11,14,17-ETA supplementation for UV protection were identified in the available literature. Evidence remains preliminary.

6.6 Cancer Biology (Mead Acid / 20:3n-9)

Mead acid inhibits the development and progression of mammary carcinogenesis by suppressing the proliferation of cancer cells, including the human breast cancer cell lines MCF-7 and KPL-1. This is in vitro evidence from cultured human cancer cell lines.

However, data from the same isomer in squamous cell carcinoma cell models points in the opposite direction. Eicosatrienoic acid (ETA 5,8,11, n-9) is abnormally increased by essential fatty acid deficiency (EFAD), a condition associated with alterations of cell proliferation and differentiation. In comparison to certain EFAs, addition of ETA at low concentration resulted in a reduction in the expression of the cell-cell adhesion molecule E-cadherin and increased invasion of Matrigel by human squamous cell carcinoma (SCC) cells in vitro. At higher concentrations, ETA stimulated the growth of SCC cells.

For DGLA: the metabolites of DGLA, including 15-HETrE and PGE1, possess both anti-inflammatory and anti-proliferative properties. PGE1 could also induce growth inhibition and differentiation of cancer cells. Although the mechanism of DGLA has not yet been fully elucidated, it is significant to anticipate the antitumor potential benefits from DGLA.

Evidence strength: All cancer-related evidence is at the level of cell-culture and in-vitro studies. Results are not consistent across cell types for Mead acid. No human clinical trial data are available. This area must be characterized as highly preliminary, with no basis for clinical conclusions.

6.7 Cystic Fibrosis (Mead Acid)

Recent pathological and epidemiological studies on Mead acid raise the possibility of its effects on inflammation, cancer, dermatitis, and cystic fibrosis, suggesting it is an endogenous multifunctional PUFA. Abnormal PUFA profiles, including elevated Mead acid alongside specific essential fatty acid imbalances, have been documented in cystic fibrosis patients. The biologic effects of fatty acids depend not only on the absolute levels but also on the ratio of n-6 to n-3 fatty acids. In cystic fibrosis there is an increased ratio of arachidonic to docosahexaenoic acid.

Evidence strength: Observational/epidemiological associations only. No controlled interventional studies of eicosatrienoic acid in cystic fibrosis patients were identified.

6.8 Essential Fatty Acid Deficiency in Special Populations

Mead acid elevation has clinical utility as a diagnostic marker across several vulnerable populations. Fat supply, especially that of EFAs, may be insufficient in children with restricted diets due to different malabsorption syndromes and even due to food allergy. Thus, the production of Mead acid is indirectly associated with the supply of EFAs in the diet, and an elevated Mead acid in serum is an indicator of essential fatty acid deficiency.

Essential fatty acid deficiency is a rare but serious condition with significant consequences including delayed growth and development, decreased immune response, and reproductive dysfunction. EFAD is of particular concern in vulnerable populations such as preterm infants and those receiving long-term parenteral nutrition.

Essential fatty acid deficiency induces skin rash, alopecia, growth disorders and reproductive abnormalities, accompanied by the appearance of Mead acid in the blood.

7. Body Systems and Health Areas of Association

• Inflammatory/Immune System: All three isomers interact with the eicosanoid-generating enzymes (COX, LOX) and thereby modulate production of prostaglandins, thromboxanes, and leukotrienes. DGLA generates anti-inflammatory series-1 prostaglandins; Mead acid inhibits LTB4 synthesis.
• Skin and Integumentary System: Mead acid has been studied in contact dermatitis models; omega-3 ETA has been investigated for UV photoprotection; DGLA (via GLA precursors) has been studied in atopic dermatitis and rosacea.
• Cardiovascular System: DGLA-derived PGE1 inhibits platelet aggregation and thrombus formation, produces vasodilation, and has been associated in observational data with cardiovascular risk markers. Mead acid has been referenced in thrombosis research.
• Nutritional/Metabolic Status Assessment: Mead acid (20:3n-9) serves as the triene component of the Holman Index for clinical diagnosis of essential fatty acid deficiency.
• Oncology (preliminary only): In-vitro evidence — both supportive and cautionary — exists for Mead acid and DGLA in various cancer cell lines. No human data are available.
• Respiratory System (cystic fibrosis): Epidemiological associations between abnormal Mead acid levels and cystic fibrosis have been reported; no interventional data are available.
• Bone: Hamazaki et al. reported depressive effects of 5,8,11-eicosatrienoic acid (20:3n-9) on osteoblasts in a preclinical study, suggesting possible relevance to bone metabolism, though this remains at the basic-research level.

8. Dosage Forms and Dosages Reported in Studies

Because eicosatrienoic acid isomers are not widely available as standalone supplements, most dosage information in the literature relates to DGLA, which has been the most studied isomer in intervention trials.

• DGLA — human safety/bioavailability trial: DGLA is expected to show anti-allergic activity. Supplementation with DGLA-enriched oil (450 mg as free DGLA) for 4 weeks was examined in healthy adults in a randomized controlled study. The DGLA composition in total fatty acids of serum phospholipids increased from 2.0 to 3.4% and returned to the initial level after a 4-week washout.
• DGLA — human allergic rhinitis RCT: Each subject received four 250-mg capsules providing 314 mg DGLA/day for 15 weeks.
• Mead acid (n-9 ETrA) — animal dietary supplementation study: An ETrA-rich oil from cultured fungus was used to prepare diets with varying levels of ETrA (0–8 g/kg diet) in combination with linoleic acid.
• Omega-3 ETA — animal topical study: Female HR-1 hairless mice were topically treated with vehicle only, 0.1% ETA, or 1% ETA once a day for 3 successive days after UV irradiation (200 mJ/cm²) on dorsal skin.
• GLA (DGLA precursor) — atopic dermatitis open study: Evening primrose oil (4–6 g) was administered daily for 12 weeks.
• Typical trial dose range for DGLA (summary from clinical literature): Typical trial doses used in human studies range from 314–450 mg DGLA/day.

No established recommended dietary intake, tolerable upper intake level, or therapeutic dose has been set by any major health authority (NIH, EFSA, WHO) for any eicosatrienoic acid isomer as a supplement.

9. Safety Considerations and Interactions

9.1 DGLA (20:3n-6)

In a 4-week randomized controlled study supplementing 450 mg DGLA per day in healthy adults, no side effects or changes in blood biochemical parameters were observed. The results indicate that serum DGLA content can be safely increased by supplementation with 450 mg DGLA under these conditions.

A defect in the activity of Δ6-desaturase and/or Δ5-desaturase may be one factor in the initiation and progression of inflammatory conditions. The potential of GLA and DGLA administrations as curative or ameliorating therapies in inflammatory conditions and malignancies appears modest at best.

Because DGLA and its downstream metabolite PGE1 have platelet-inhibiting and vasodilatory properties, caution is warranted in individuals taking anticoagulant or antiplatelet medications. In lab and ex-vivo platelet models, DGLA can be turned into 15-HETrE, which dampens platelet aggregation and interferes with pro-thrombotic signaling cascades. This pharmacological action could potentially potentiate the effects of anticoagulants or antiplatelet drugs such as warfarin, aspirin, or clopidogrel, though no specific drug–interaction studies for direct DGLA supplementation were identified in the peer-reviewed literature.

With GLA (the DGLA precursor), responses vary with genetics (FADS1/FADS2), micronutrient status (zinc, magnesium), insulin resistance, and age. This genetic variability in conversion efficiency means that indirect DGLA delivery through GLA-rich oils has an unpredictable dose-response profile across individuals.

9.2 GLA-Containing Oils (Precursor Sources)

Quality and safety vary by source; for example, unpurified borage can carry pyrrolizidine alkaloids that harm the liver. This is a documented safety concern for borage oil products not certified as pyrrolizidine alkaloid-free.

9.3 Mead Acid (20:3n-9)

In the context of EFAD, elevated Mead acid is a marker of a deficiency state, not a therapeutic target. Supplementation with Mead acid has shown therapeutic effects on indomethacin-induced bowel lesions by suppressing leukotriene B4 synthesis in animal studies. Mead acid's effects on human platelet biology have also been noted in older research: Lagarde et al. reported a potentiating effect of 5,8,11-eicosatrienoic acid on human platelet aggregation, suggesting a potential pro-thrombotic effect at the platelet level — the opposite direction from the platelet effects of DGLA. This is a safety consideration of note, though it derives from older in vitro/ex-vivo work. No controlled human safety study for Mead acid as a dietary supplement was identified.

The cell-culture evidence that, at higher concentrations, Mead acid stimulated the growth of squamous cell carcinoma cells underscores the need for caution in any therapeutic application; at higher concentrations, ETA stimulated the growth of SCC cells in vitro. This is a preclinical signal, not a clinical finding, but it represents a data point warranting further investigation before any therapeutic use is contemplated.

9.4 Sufficiency of the Evidence Base

The main problem with all of these PUFAs lies in their nutritional applications not being sufficiently clear. The overall safety profile of eicosatrienoic acid isomers as intentional dietary supplements is inadequately characterized in the current peer-reviewed literature. Most published safety-relevant data arise from animal experiments, short-term human pharmacokinetic studies, or long-term observational associations. Controlled long-term human safety data are absent.

10. Evidence Summary and Current Research Status

The three biologically relevant eicosatrienoic acid isomers occupy very different places on the evidence continuum:

• Mead acid (20:3n-9) has the best-established clinical utility, not as a supplement but as a diagnostic biomarker. Its role as the triene component of the Holman Index for EFAD diagnosis is supported by decades of clinical and laboratory data. Its potential therapeutic applications (anti-inflammatory, anti-cancer, skin conditions) are supported only by animal and in vitro work, with some mechanistic plausibility. An increasing number of studies have reported the relation between Mead acid and diseases such as inflammation, cancer, dermatitis, and cystic fibrosis, and epidemiological data have been reported recently.
• DGLA (20:3n-6) has the most developed human intervention data of the three isomers. One randomized, double-blind, placebo-controlled trial of direct DGLA supplementation exists (in pollen allergy), along with pharmacokinetic safety data in healthy adults. Mechanistic data in cell and animal systems are extensive. Clinical data remain scarce and further well-designed studies should be actively promoted.
• Omega-3 ETA (11,14,17-ETA, 20:3n-3) has human skin biopsy data supporting its biological relevance in UV-induced photodamage and aging, and animal topical application data suggesting photoprotective effects. No human interventional trials of ETA supplementation or topical application for photoprotection were identified.

References

• Kasuga K et al. "The physiological and pathological properties of Mead acid, an endogenous multifunctional n-9 polyunsaturated fatty acid." Lipids in Health and Disease 2023;22(1):173. PMC Full Text
• Kasuga K et al. "The physiological and pathological properties of Mead acid, an endogenous multifunctional n-9 polyunsaturated fatty acid." PubMed abstract
• Tsuduki T et al. "Identification of genes and pathways involved in the synthesis of Mead acid (20:3n-9)." PubMed
• Mead JF, Slaton WH. "Isolation of 5,8,11-eicosatrienoic acid from fat-deficient rats." J Biol Chem. 1956;219(2):705–9. PubMed
• Cleland LG et al. "Dietary (n-9) eicosatrienoic acid from a cultured fungus inhibits leukotriene B4 synthesis in rats." J Nutr. 1996;126(6):1534–40. PubMed
• Cleland LG et al. "Effect of dietary n-9 eicosatrienoic acid on the fatty acid composition of plasma lipid fractions and tissue phospholipids." Lipids. 1996;31(8):829–37.
• Aro H et al. "Food allergy in small children carries a risk of essential fatty acid deficiency, as detected by elevated serum Mead acid proportion." PMC
• Jin XJ et al. "Prevention of UV-induced skin damages by 11,14,17-eicosatrienoic acid in hairless mice in vivo." J Korean Med Sci. 2010;25(6):930–937. PMC
• Oh IK et al. "Skin aging and photoaging alter fatty acids composition, including 11,14,17-eicosatrienoic acid, in the epidermis of human skin." J Korean Med Sci. 2010;25(6):980–983. PMC
• Mogensen TH et al. "Dihomo-γ-Linolenic Acid (20:3n-6)—Metabolism, Derivatives, and Potential Significance in Chronic Inflammation." Nutrients. 2023;15(3):594. PMC
• Ge Y et al. "Multiple roles of dihomo-γ-linolenic acid against proliferation diseases." Lipids Health Dis. 2012;11:25. PMC
• Dawczynski C et al. "Dihomo-γ-linolenic acid inhibits several key cellular processes associated with atherosclerosis." PMC
• Ringbom T et al. "Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2." PubMed
• Kawashima H et al. "Supplementation of Dihomo-γ-Linolenic Acid for Pollen-Induced Allergic Symptoms in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Trial." PMC
• Kawashima H et al. "Oral supplementation with dihomo-γ-linolenic acid (DGLA)-enriched oil increases serum DGLA content in healthy adults." PubMed
• Senapati S et al. "Gamma-Linolenic Acid Levels Correlate with Clinical Efficacy of Evening Primrose Oil in Patients with Atopic Dermatitis." PMC
• Wolff M et al. "Essential fatty acid deficiency in parenteral nutrition: Historical perspective and modern solutions, a narrative review." Nutr Clin Pract. 2025. PMC
• Mundi MS et al. "Redefining essential fatty acids in the era of novel intravenous lipid emulsions." PMC
• Abrams SA et al. "In defense of the Holman index: Defining fatty acid deficiency." Nutrition. 2025. ScienceDirect
• Hamazaki K et al. "Mead acid inhibits retinol-induced irritant contact dermatitis via peroxisome proliferator-activated receptor alpha." PMC
• Tong L et al. "Eicosatrienoic acid (20:3 n-9) inhibits the expression of E-cadherin and desmoglein in human squamous cell carcinoma in vitro." PubMed
• Cleland LG et al. "Effect of dietary n-9 eicosatrienoic acid on the fatty acid composition of plasma lipid fractions." PubMed
• Wikipedia: Eicosatrienoic acid
• ScienceDirect Topics: Eicosatrienoic Acid
• ScienceDirect Topics: Icosatrienoic Acid (Nursing and Health Professions)
• Linus Pauling Institute, Oregon State University: Essential Fatty Acids and Skin Health
• Seo YJ et al. "A Randomized, Placebo-Controlled Trial of Gamma Linolenic Acid as an Add-on Therapy to Minocycline for the Treatment of Rosacea." PMC